RESUMO
Hemp seed, the dried fruit of Cannabis sativa L. (Moraceae), has been extensively documented as a folk source of food due to its nutritional and functional value. This study evaluated the antidepressant effect of hemp seed oil (HSO) during its estrogen-like effect in Perimenopausal depression (PMD) rats induced by ovariectomy combined with chronic unpredictable mild stress (OVX-CUMS). Female SD rats (SPF, 10 weeks, sham operated group, ovariectomy (OVX) model group, ovariectomy - chronic unpredictable mild stress (OVX-CUMS) group, HSO + OVX-CUMS group, fluoxetine (FLU) + OVX-CUMS group, n=8) were subjected to treatment with HSO (4.32 g/kg) or fluoxetine (10 mg/kg) for 28 days (20 mL/kg by ig). Sucrose preference test (SPT), forced swimming test (FST), open field test (OFT), estrogen receptor α (ERα) and estrogen receptor ß (ERß) expression, estradiol (E2), follicle stimulating hormone (FSH), luteinizing hormone (LH), cortisol (CORT), adrenocorticotropic hormone (ACTH), corticotropin releasing hormone (CRH), norepinephrine (NE), 5-hydroxytryptamine (5-HT) and 5-hydroxyindoleacetic acid (5HIAA) levels are measured to evaluate the function of the hypothalamic-pituitary-ovarian (HPO) and hypothalamic-pituitary-adrenal (HPA) axis. The results showed that OVX-CUMS significantly decrease sucrose preference rate in SPT, increase immobility time in FST and OFT, and decrease movement distance and stand-up times in OFT. HSO treatment significantly improves depression-like behaviors, upregulates the expression of ERα and ERß, improves HPO axis function by increasing E2 levels and decreasing FSH and LH levels, reverses HPA axis hyperactivation by decreasing CORT, ACTH, and CRH levels, and upregulates NE, 5-HT, and 5HIAA levels in model rats. The findings suggested that HSO could improve depression-like behavior in OVX-CUMS rats by regulating HPO/HPA axis function and neurotransmitter disturbance.
Assuntos
Cannabis , Depressão , Ratos , Feminino , Animais , Depressão/tratamento farmacológico , Depressão/prevenção & controle , Sistema Hipotálamo-Hipofisário/metabolismo , Cannabis/metabolismo , Receptor alfa de Estrogênio/metabolismo , Fluoxetina/metabolismo , Fluoxetina/farmacologia , Serotonina/metabolismo , Serotonina/farmacologia , Receptor beta de Estrogênio/metabolismo , Perimenopausa , Ratos Sprague-Dawley , Sistema Hipófise-Suprarrenal/metabolismo , Hormônio Adrenocorticotrópico/metabolismo , Hormônio Adrenocorticotrópico/farmacologia , Hormônio Foliculoestimulante/metabolismo , Hormônio Foliculoestimulante/farmacologia , Sacarose , Estresse Psicológico/tratamento farmacológico , Modelos Animais de DoençasRESUMO
BACKGROUND: Bromelain is a complex mixture of protease enzyme extract from the fruit or stem of the pineapple plant and it has a history of folk medicine use. It is known to have a wide range of biological actions and it is most commonly used as an anti-inflammatory agent, though scientists have also discovered its potential as an anticancer and antimicrobial agent, it has been reported to have positive effects on the respiratory, digestive, circulatory systems and potentially on the immune system. OBJECTIVE: This study was designed to investigate the antidepressant potential of Bromelain in the chronic unpredictable stress (CUS) model of depression. METHODS: We studied the antioxidant activity, and neuroprotective effect of Bromelain by analyzing the fear and anxiety behavior, antioxidants, and neurotransmitter levels, and also by analyzing the histopathological changes. Adult male Wistar albino rats were divided into 5 groups, Control; Bromelain; CUS; CUS + Bromelain, CUS + fluoxetine. Animals of the CUS group, CUS + Bromelain group, and CUS + Fluoxetine group were exposed to CUS for 30 days. Animals of the Bromelain group and CUS + Bromelain group were treated orally with 40 mg/kg Bromelain throughout the period of CUS whereas, the positive control group was treated with fluoxetine. RESULTS: Results showed a significant decrease in oxidative stress marker (lipid peroxidation), and the stress hormone cortisol, in Bromelain-treated CUS-induced depression. Bromelain treatment in CUS has also resulted in a significant increase in neurotransmitter levels, which indicates the efficacy of Bromelain to counteract the monamine neurotransmitter changes in depression by increasing their synthesis and reducing their metabolism. In addition, the antioxidant activity of Bromelain prevented oxidative stress in depressed rats. Also, hematoxylin and eosin staining of hippocampus sections has revealed that Bromelain treatment has protected the degeneration of nerve cells by chronic unpredictable stress exposure. CONCLUSION: This data provides evidence for the antidepressant-like action of Bromelain by preventing neurobehavioral, biochemical, and monoamine alterations.
Assuntos
Depressão , Fluoxetina , Ratos , Animais , Fluoxetina/metabolismo , Fluoxetina/farmacologia , Depressão/tratamento farmacológico , Depressão/metabolismo , Antioxidantes/farmacologia , Antioxidantes/uso terapêutico , Antioxidantes/metabolismo , Ratos Wistar , Bromelaínas/farmacologia , Bromelaínas/uso terapêutico , Antidepressivos/farmacologia , Antidepressivos/uso terapêutico , Hipocampo/metabolismo , Modelos Animais de DoençasRESUMO
OBJECTIVE: To investigate the role of hippocampal neurodevelopment in the antidepressant effect of baicalin. METHODS: Forty male Institute of Cancer Research mice were divided into control, corticosterone (CORT, 40 mg/kg), CORT+baicalin-L (25 mg/kg), CORT+baicalin-H (50 mg/kg), and CORT+fluoxetine (10 mg/kg) groups according to a random number table. An animal model of depression was established by chronic CORT exposure. Behavioral tests were used to assess the reliability of depression model and the antidepressant effect of baicalin. In addition, Nissl staining and immunofluorescence were used to evaluate the effect of baicalin on hippocampal neurodevelopment in mice. The protein and mRNA expression levels of neurodevelopment-related factors were detected by Western blot analysis and real-time polymerase chain reaction, respectively. RESULTS: Baicalin significantly ameliorated the depressive-like behavior of mice resulting from CORT exposure and promoted the development of dentate gyrus in hippocampus, thereby reversing the depressive-like pathological changes in hippocampal neurons caused by CORT neurotoxicity. Moreover, baicalin significantly decreased the protein and mRNA expression levels of glycogen synthase kinase 3ß (GSK3ß), and upregulated the expression levels of cell cycle protein D1, p-mammalian target of rapamycin (mTOR), doublecortin, and brain-derived neurotrophic factor (all P<0.01). There were no significant differences between baicalin and fluoxetine groups (P>0.05). CONCLUSION: Baicalin can promote the development of hippocampal neurons via mTOR/GSK3ß signaling pathway, thus protect mice against CORT-induced neurotoxicity and play an antidepressant role.
Assuntos
Corticosterona , Fluoxetina , Masculino , Animais , Camundongos , Fluoxetina/farmacologia , Fluoxetina/uso terapêutico , Fluoxetina/metabolismo , Depressão/tratamento farmacológico , Depressão/induzido quimicamente , Glicogênio Sintase Quinase 3 beta/metabolismo , Reprodutibilidade dos Testes , Antidepressivos/farmacologia , Hipocampo , Serina-Treonina Quinases TOR/metabolismo , RNA Mensageiro/genética , Comportamento Animal , Modelos Animais de Doenças , Mamíferos/genética , Mamíferos/metabolismoRESUMO
The K+ ion channels comprising the two-pore domain (K2P) family have specific biophysical roles in generating the critical regulatory K+ current. Ion flow through K2P channels and, implicitly, channel regulation is mediated by diverse metabolic and physical inputs such as mechanical stimulation, interaction with lipids or endogenous regulators, intra- or extracellular pH, and phosphorylation, while their function can be finely tuned by chemical compounds. In the latter category, some drug-channel interactions can lead to side effects or have clinical action, while identifying novel chemical modulators of K2Ps is an area of intense research. Due to their cellular and therapeutic importance, much attention was turned to these channels in recent years and several experimental approaches have pinpointed the molecular determinants of K2P chemical modulation. Given their unique structural features and properties, chemical modulators act on K2P channels in multiple and diverse ways. In this review, the particularities of K2P modulation by chemical compounds, such as binding modality, affinity, or position, are identified, synthesized, and linked to structural and functional properties in order to refer to how activators and blockers modify channel function and vice versa, focusing on specificity related to protein structure (and its modification) and cross-linking information among different subfamilies.
Assuntos
Fluoxetina/química , Fluoxetina/metabolismo , Moduladores de Transporte de Membrana/química , Moduladores de Transporte de Membrana/metabolismo , Canais de Potássio de Domínios Poros em Tandem/metabolismo , Avaliação Pré-Clínica de Medicamentos , Regulação da Expressão Gênica , Humanos , Lipídeos/química , Modelos Moleculares , Estrutura Molecular , Fosforilação , Ligação Proteica , Conformação Proteica , Relação Estrutura-AtividadeRESUMO
Obsessive-compulsive disorder (OCD) is a common neuropsychiatric disease affecting about 2% of the general population. It is characterized by persistent intrusive thoughts and repetitive ritualized behaviors. While gene variations, malfunction of cortico-striato-thalamo-cortical (CSTC) circuits, and dysregulated synaptic transmission have been implicated in the pathogenesis of OCD, the underlying mechanisms remain largely unknown. Here we show that OCD-like behavior in mice is caused by deficiency of SPRED2, a protein expressed in various brain regions and a potent inhibitor of Ras/ERK-MAPK signaling. Excessive self-grooming, reflecting OCD-like behavior in rodents, resulted in facial skin lesions in SPRED2 knockout (KO) mice. This was alleviated by treatment with the selective serotonin reuptake inhibitor fluoxetine. In addition to the previously suggested involvement of cortico-striatal circuits, electrophysiological measurements revealed altered transmission at thalamo-amygdala synapses and morphological differences in lateral amygdala neurons of SPRED2 KO mice. Changes in synaptic function were accompanied by dysregulated expression of various pre- and postsynaptic proteins in the amygdala. This was a result of altered gene transcription and triggered upstream by upregulated tropomyosin receptor kinase B (TrkB)/ERK-MAPK signaling in the amygdala of SPRED2 KO mice. Pathway overactivation was mediated by increased activity of TrkB, Ras, and ERK as a specific result of SPRED2 deficiency and not elicited by elevated brain-derived neurotrophic factor levels. Using the MEK inhibitor selumetinib, we suppressed TrkB/ERK-MAPK pathway activity in vivo and reduced OCD-like grooming in SPRED2 KO mice. Altogether, this study identifies SPRED2 as a promising new regulator, TrkB/ERK-MAPK signaling as a novel mediating mechanism, and thalamo-amygdala synapses as critical circuitry involved in the pathogenesis of OCD.
Assuntos
Transtorno Obsessivo-Compulsivo/metabolismo , Transtorno Obsessivo-Compulsivo/patologia , Proteínas Repressoras/fisiologia , Tonsila do Cerebelo/metabolismo , Animais , Comportamento Compulsivo/metabolismo , Corpo Estriado/metabolismo , MAP Quinases Reguladas por Sinal Extracelular/fisiologia , Fluoxetina/metabolismo , Sistema de Sinalização das MAP Quinases/fisiologia , Camundongos , Camundongos Knockout , Neurônios/metabolismo , Comportamento Obsessivo/fisiopatologia , Receptor trkB/fisiologia , Proteínas Repressoras/genética , Transdução de Sinais , Sinapses/metabolismo , Transmissão Sináptica/fisiologia , Tálamo/metabolismoRESUMO
Fluoxetine (FLX), a selective serotonin reuptake inhibitor, is widespread in aquatic environments. Despite its reported effects on behavior and reproduction in aquatic species, little is known about the effects of FLX on cellular detoxification and defense system in bivalves. Here, the adult Asian clam (Corbicula fluminea) was exposed to 0.5, 5, and 50 µg L(-1) FLX for 30 d. Siphoning behavior was inhibited by treatment with 50 µg L(-1) FLX. Additionally, superoxide dismutase (SOD) activity in the gills and digestive glands significantly decreased (p<0.05) with 5 and 50 µg L(-1) FLX treatments, whereas catalase (CAT) activity and malondialdehyde (MDA) content markedly increased (p<0.05). Moreover, transcription of thioredoxin reductase (TR), glutathione peroxidase (GPx) and Glutathione S-transferase pi class (GSTpi) was significantly upregulated (p<0.05), whereas glutathione reductase (GR) was markedly downregulated (p<0.05). These findings suggest that FLX affects behavior and induces oxidative stress in C. fluminea. The downregulation of ATP-binding cassette (ABC) transportor genes (ABCB1, ABCC1 and ABCG2) transporter genes indicated that FLX might suppress the multixenobiotic resistance (MXR) system in C. fluminea. Our results provide new insights into the adverse effects of FLX on the cellular detoxification and MXR system of C. fluminea.
Assuntos
Comportamento Animal/efeitos dos fármacos , Corbicula/efeitos dos fármacos , Fluoxetina/toxicidade , Poluentes Químicos da Água/toxicidade , Análise de Variância , Animais , Antioxidantes/metabolismo , Catalase/metabolismo , China , Corbicula/genética , Primers do DNA/genética , DNA Complementar/genética , Relação Dose-Resposta a Droga , Fluoxetina/metabolismo , Brânquias/metabolismo , Glutationa Peroxidase/metabolismo , Glutationa Redutase/metabolismo , Malondialdeído/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Reação em Cadeia da Polimerase em Tempo Real , Superóxido Dismutase/metabolismo , Tiorredoxina Dissulfeto Redutase/metabolismo , Poluentes Químicos da Água/análiseRESUMO
We examined the effects of genistein, one of the major soy phytoestrogens, on the activity of noradrenaline transporter (NAT) and serotonin transporter. Treatment with genistein (10 nM-10 microM) for 20 min stimulated [(3)H]noradrenaline (NA) uptake by SK-N-SH cells. Genistein also stimulated [(3)H]NA uptake and [(3)H]serotonin uptake by NAT and serotonin transporter transiently transfected COS-7 cells, respectively. Kinetics analysis of the effect of genistein on NAT activity in NAT-transfected COS-7 cells revealed that genistein significantly increased the maximal velocity of NA transport with little or no change in the affinity. Scatchard analysis of [(3)H]nisoxetine binding to NAT-transfected COS-7 cells showed that genistein increased the maximal binding without altering the dissociation constant. Although genistein is also known to be an inhibitor of tyrosine kinases, daidzein, another soy phytoestrogen and an inactive genistein analogue against tyrosine kinases, had little effect on [(3)H]NA uptake by SK-N-SH cells. The stimulatory effects on NAT activity were observed by treatment of tyrphostin 25, an inhibitor of epidermal growth factor receptor tyrosine kinase, whereas orthovanadate, a protein tyrosine phosphatase inhibitor, suppressed [(3)H]NA uptake by NAT-transfected COS-7 cells. These findings suggest that genistein up-regulates the activity of neuronal monoamine transporters probably through processes involving protein tyrosine phosphorylation.
Assuntos
Genisteína/farmacologia , Glycine max/química , Proteínas da Membrana Plasmática de Transporte de Norepinefrina/efeitos dos fármacos , Fitoestrógenos/farmacologia , Proteínas da Membrana Plasmática de Transporte de Serotonina/efeitos dos fármacos , Animais , Células COS , Linhagem Celular Tumoral , Chlorocebus aethiops , Inibidores Enzimáticos/farmacologia , Estradiol/análogos & derivados , Estradiol/farmacologia , Fluoxetina/análogos & derivados , Fluoxetina/metabolismo , Fulvestranto , Humanos , Neuroblastoma , Norepinefrina/metabolismo , Proteínas da Membrana Plasmática de Transporte de Norepinefrina/genética , Proteínas da Membrana Plasmática de Transporte de Norepinefrina/fisiologia , Proteínas Tirosina Fosfatases/antagonistas & inibidores , Proteínas Tirosina Quinases/antagonistas & inibidores , Receptores de Estrogênio/antagonistas & inibidores , Serotonina/metabolismo , Proteínas da Membrana Plasmática de Transporte de Serotonina/genética , Proteínas da Membrana Plasmática de Transporte de Serotonina/fisiologia , Transfecção , Trítio , Vanadatos/farmacologiaRESUMO
In this study, we extend previous work on iron deficiency and dopamine (DA) transporters to include an examination of central serotonin (5-HT) and noradrenergic (NE) transporters. Rats were fed either iron deficient (ID) or iron adequate (CN) diets from weaning until adulthood. In males, an additional group of iron deficient animals (IR) were given iron supplementation. DA, 5-HT, and NE transporter binding was done in situ on thin sections. ID males, but not females, decreased DA transporter binding in the nucleus accumbens, caudate putamen and substantia nigra by 20-40%. ID males also had a 20-30% reduction in 5-HT transporter binding in several areas (nucleus accumbens, olfactory tubercle, colliculus) while in ID females there was 15-25% increased serotonin transporter binding in the olfactory tubercle, zona incerta, anteroventral thalamic nucleus and vestibular nucleus. Iron deficiency reduced 3H-nisoxetine binding to the NE transporter in locus ceruleus and anteroventral thalamic nucleus in males but not females. Only some of the changes observed in DA, serotonin and NE transporter binding were reversible by iron supplementation. These findings show that iron deficiency affects monoamine systems related to homeostasis and in most cases males appear to be more vulnerable than females.
Assuntos
Encéfalo/metabolismo , Fluoxetina/análogos & derivados , Deficiências de Ferro , Glicoproteínas de Membrana/metabolismo , Proteínas de Membrana Transportadoras/metabolismo , Proteínas do Tecido Nervoso/metabolismo , Simportadores/metabolismo , Animais , Núcleo Caudado/metabolismo , Proteínas da Membrana Plasmática de Transporte de Dopamina , Feminino , Fluoxetina/metabolismo , Ferro/administração & dosagem , Masculino , Proteínas da Membrana Plasmática de Transporte de Norepinefrina , Núcleo Accumbens/metabolismo , Condutos Olfatórios/metabolismo , Ratos , Ratos Sprague-Dawley , Proteínas da Membrana Plasmática de Transporte de Serotonina , Caracteres Sexuais , Substância Negra/metabolismo , TrítioRESUMO
There is increasing evidence that central noradrenaline (NA) transport mechanisms are implicated in the central nervous system complications of acute liver failure. In order to assess this possibility, binding sites for the high affinity NA transporter ligand [3H]-nisoxetine were measured by quantitative receptor autoradiography in the brains of rats with acute liver failure resulting from hepatic devascularization and in appropriate controls. In vivo microdialysis was used to measure extracellular brain concentrations of NA. Severe encephalopathy resulted in a significant loss of [3H]-nisoxetine sites in frontal cortex and a concomitant increase in extracellular brain concentrations of NA in rats with acute liver failure. A loss of transporter sites was also observed in thalamus of rats with acute liver failure. This loss of NA transporter sites could result from depletion of central NA stores due to a reserpine-like effect of ammonia which is known to accumulate to millimolar concentrations in brain in ischemic liver failure. Impaired NA transport and the consequent increase in synaptic concentrations and increased stimulation of neuronal and astrocytic noradrenergic receptors could be implicated in the pathogenesis of the encephalopathy and brain edema characteristic of acute liver failure.
Assuntos
Proteínas de Transporte/metabolismo , Lobo Frontal/metabolismo , Encefalopatia Hepática/metabolismo , Isquemia/complicações , Falência Hepática/complicações , Fígado/irrigação sanguínea , Proteínas do Tecido Nervoso/deficiência , Simportadores , Doença Aguda , Amônia/metabolismo , Animais , Edema Encefálico/etiologia , Edema Encefálico/metabolismo , Fluoxetina/análogos & derivados , Fluoxetina/metabolismo , Encefalopatia Hepática/etiologia , Masculino , Proteínas do Tecido Nervoso/metabolismo , Norepinefrina/metabolismo , Proteínas da Membrana Plasmática de Transporte de Norepinefrina , Derivação Portocava Cirúrgica , Ratos , Ratos Sprague-Dawley , Tálamo/metabolismoRESUMO
The mouse "Purkinje cell degeneration" (pcd) is characterized by a primary loss of Purkinje cells, as well as by retrograde and secondary partial degeneration of cerebellar granule cells and inferior olivary neurons; this neurological mutant can be considered as an animal model of human degenerative ataxia. To determine the consequences of this cerebellar pathology on the noradrenergic system, noradrenaline transporters as well as alpha1-, alpha2- and beta-adrenergic receptors were evaluated by quantitative ligand binding autoradiography in adult control and pcd mice using, respectively, [3H]nisoxetine, [3H]prazosin, [3H]idazoxan and [3H]CGP12177. In cerebellar cortex and deep nuclei of pcd mutants, [3H]nisoxetine labelling of noradrenaline transporters was higher than in control mice. However, when binding densities were corrected by surface area, they remained unchanged in the cerebellar cortex but associated with 25% and 40% lower levels of labelling of alpha1 and beta receptors, as well as a very important increase (275%) of alpha2 receptors. In deep cerebellar nuclei, surface corrections did not reveal any changes either in transporter or in receptor densities. Higher densities of [3H]nisoxetine labelling were found in several regions related with the cerebellum, namely inferior olive, inferior colliculus, vestibular, reticular, pontine, raphe and red nuclei, as well as in primary motor and sensory cerebral cortex; they may reflect an increased noradrenergic innervation related to motor adjustments for the cerebellar dysfunction. Increased [3H]nisoxetine labelling was also measured in vegetative brainstem regions and in dorsal hypothalamus, implying altered autonomic functions and possible compensation in pcd mutants. Other changes found in extracerebellar regions affected by the mutation, such as thalamus and the olfactory system implicated both noradrenaline transporters and adrenergic receptors. In contrast to the important alterations of the noradrenergic system in cerebellar cortex, the lack of receptor changes in deep cerebellar nuclei suggests that local adaptations may be sufficient to minimize the consequence of the cerebellar atrophy on motor control. An intense labelling by [3H]idazoxan of the inner third of the molecular layer was a novel, albeit unexplained finding, and could represent a postsynaptic subset of alpha2-adrenergic receptors.
Assuntos
Norepinefrina/análise , Norepinefrina/metabolismo , Receptores Adrenérgicos/análise , Receptores Adrenérgicos/metabolismo , Degenerações Espinocerebelares/metabolismo , Antagonistas Adrenérgicos alfa/metabolismo , Antagonistas Adrenérgicos alfa/farmacologia , Antagonistas Adrenérgicos beta/metabolismo , Antagonistas Adrenérgicos beta/farmacologia , Animais , Autorradiografia , Gânglios da Base/química , Tronco Encefálico/química , Córtex Cerebral/química , Modelos Animais de Doenças , Feminino , Fluoxetina/análogos & derivados , Fluoxetina/metabolismo , Fluoxetina/farmacologia , Hipotálamo/química , Idazoxano/metabolismo , Idazoxano/farmacologia , Sistema Límbico/química , Camundongos , Camundongos Mutantes Neurológicos , Norepinefrina/antagonistas & inibidores , Prazosina/metabolismo , Prazosina/farmacologia , Propanolaminas/metabolismo , Propanolaminas/farmacologia , Células de Purkinje/química , Células de Purkinje/metabolismo , Ensaio Radioligante , Receptores Adrenérgicos alfa 1/análise , Receptores Adrenérgicos alfa 1/metabolismo , Receptores Adrenérgicos alfa 2/análise , Receptores Adrenérgicos alfa 2/metabolismo , Receptores Adrenérgicos beta/análise , Receptores Adrenérgicos beta/metabolismo , Degenerações Espinocerebelares/genética , Tálamo/química , TrítioRESUMO
Long-term exposure to fluoxetine produces a desensitization of hypothalamic postsynaptic 5-hydroxytryptamine (5-HT)1A receptors, indicated by a substantial inhibition of the 5-HT1A receptor-mediated stimulation of oxytocin and adrenocorticotropic hormone (ACTH) secretion. The present study investigated the time course and mechanism of this desensitization after discontinuation of fluoxetine administration. Male rats were injected with saline or fluoxetine (10 mg/kg/day, i.p.) for 14 days and were challenged with a 5-HT1A agonist, [8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT) 50 microg/kg, s.c.] 2, 4, 7, 14, 28, or 60 days post-treatment. In control animals, 8-OH-DPAT significantly increased (approximately 15-fold) plasma levels of oxytocin and ACTH. At 2 days post-treatment, oxytocin and ACTH responses to 8-OH-DPAT were reduced by 74% and 68%, respectively. During further withdrawal from fluoxetine, there was a gradual increase in the oxytocin response toward control levels. However, even 60 days after discontinuation of fluoxetine, the oxytocin response was still significantly reduced by 26% compared with controls. In contrast, the suppressed ACTH response to 8-OH-DPAT (a less-sensitive indicator of desensitization) gradually returned to control levels by day 14 of withdrawal from fluoxetine. Interestingly, the sustained reductions in the hormone responses occurred in the absence of reductions in Gz or Gi protein levels in the hypothalamus. Furthermore, this desensitization was sustained in the absence of detectable levels of fluoxetine and norfluoxetine in plasma and brain tissue. These findings suggest that the sustained desensitization of hypothalamic 5-HT1A receptor systems, observed during fluoxetine withdrawal, may be due to altered interactions among the protein components of the 5-HT1A receptor system, rather than their absolute levels.
Assuntos
8-Hidroxi-2-(di-n-propilamino)tetralina/farmacologia , Fluoxetina/farmacologia , Subunidades alfa Gi-Go de Proteínas de Ligação ao GTP/antagonistas & inibidores , Subunidades alfa Gi-Go de Proteínas de Ligação ao GTP/metabolismo , Hipotálamo/ultraestrutura , Receptores de Serotonina/efeitos dos fármacos , Receptores de Serotonina/fisiologia , Inibidores Seletivos de Recaptação de Serotonina/farmacologia , Agonistas do Receptor de Serotonina/farmacologia , Síndrome de Abstinência a Substâncias/metabolismo , 8-Hidroxi-2-(di-n-propilamino)tetralina/antagonistas & inibidores , Hormônio Adrenocorticotrópico/sangue , Hormônio Adrenocorticotrópico/metabolismo , Animais , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Interações Medicamentosas , Fluoxetina/análogos & derivados , Fluoxetina/sangue , Fluoxetina/metabolismo , Hipotálamo/efeitos dos fármacos , Hipotálamo/metabolismo , Masculino , Ocitocina/sangue , Ocitocina/metabolismo , Ratos , Ratos Sprague-Dawley , Receptores 5-HT1 de Serotonina , Sensibilidade e Especificidade , Inibidores Seletivos de Recaptação de Serotonina/sangue , Inibidores Seletivos de Recaptação de Serotonina/metabolismo , Síndrome de Abstinência a Substâncias/sangueRESUMO
The present study was designed to test the hypothesis that prenatal morphine, which differentially affects hypothalamic norepinephrine content and turnover in male and female rats, has sexually dimorphic effects on the density of hypothalamic norepinephrine uptake sites in adult offspring. The binding characteristics of norepinephrine transporters were examined in the hypothalamus, preoptic area and frontal cortex of adult male and female rats exposed to morphine (5-10 mg/kg, twice daily) or saline on gestation days 11-18. There was a gender-related difference in the density of norepinephrine uptake sites measured by [3H]nisoxetine binding in the frontal cortex of saline controls, with control males having significantly fewer binding sites than control females. Prenatal morphine administration did not reverse or eliminate this difference. Additionally, prenatal morphine exposure had no effects on either the binding capacity or the affinity of norepinephrine uptake sites in the hypothalamus, preoptic area or frontal cortex of adult progeny. Thus, alterations in hypothalamic norepinephrine content and turnover following prenatal morphine exposure are not reflected in alterations in norepinephrine uptake sites. However, recent immunocytochemical work in our laboratory correlated reductions in hypothalamic norepinephrine content and turnover rate with reductions in tyrosine hydroxylase and dopamine-beta-hydroxylase fiber density in the hypothalamus of morphine-exposed female rats. Therefore, the present results may suggest that compensatory mechanisms increase the density of norepinephrine uptake sites in hypothalamic terminal fields of morphine-exposed females.
Assuntos
Analgésicos Opioides/farmacologia , Córtex Cerebral/metabolismo , Fluoxetina/análogos & derivados , Morfina/farmacologia , Efeitos Tardios da Exposição Pré-Natal , Animais , Feminino , Fluoxetina/metabolismo , Hipotálamo/efeitos dos fármacos , Hipotálamo/metabolismo , Cinética , Masculino , Terminações Nervosas/efeitos dos fármacos , Terminações Nervosas/metabolismo , Norepinefrina/metabolismo , Gravidez , Ratos , Caracteres SexuaisRESUMO
The combination of fluoxetine (FLU) and desipramine (DMI) has been reported to be useful for the treatment of depression, and these drugs are also known to undergo a metabolic drug-drug interaction because of their effects on cytochrome P-450 2D6. A procedure that separates these two drugs and norfluoxetine (NFLU), the N-demethylated metabolite of FLU, and that allows simultaneous quantification of their levels would be of value and has been developed in our laboratories. The procedure involves an initial extraction into ethyl acetate after basification of the homogenate. The organic phase is retained and taken to dryness; the residue is reconstituted in water and acetylated with acetic anhydride under slightly basic conditions. Ethyl acetate is then used to extract the acetylated compounds from the aqueous medium. The organic layer is taken to dryness and the residue reconstituted in toluene. An aliquot of the solution in toluene is injected directly into a gas chromatograph equipped with a nitrogen-phosphorus detector, a fused silica capillary column, and an integrator/printer. Maprotiline is added to the initial homogenate and carried through the procedure as the internal standard. The assay is rapid and sensitive and has been applied successfully to liver and brain tissue taken from rats treated with FLU, DMI, or the combination.
Assuntos
Antidepressivos/isolamento & purificação , Química Encefálica , Desipramina/isolamento & purificação , Fluoxetina/análogos & derivados , Fluoxetina/isolamento & purificação , Fígado/química , Animais , Antidepressivos/administração & dosagem , Antidepressivos/metabolismo , Cromatografia Gasosa , Desipramina/administração & dosagem , Desipramina/metabolismo , Interações Medicamentosas , Fluoxetina/administração & dosagem , Fluoxetina/química , Fluoxetina/metabolismo , Masculino , Espectrometria de Massas , Nitrogênio/química , Fósforo/química , Ratos , Ratos Sprague-Dawley , Padrões de Referência , Distribuição TecidualRESUMO
Due to the high level of expression of mRNA for the 5-hydroxytrytamine (5-ht7) receptor in the hypothalamus and the high affinity of 5-HT for this receptor, [3H]5-HT binding was performed in rat hypothalamus to determine whether 5-ht7 receptor binding sites are present in animal tissue. [3H]5-HT binding was performed in the presence of 100 nM pindolol, which is inactive at 5-ht7 receptors but prevents the binding of [3H]5-HT to 5-HT1A and 5-HT1B receptor binding sites. Under these conditions, [3H]5-HT bound to a binding site with an affinity of 1.94 nM. Displacement studies showed the pharmacology of the hypothalamic binding site to correlate well with the published pharmacology of the 5-ht7 receptor (r = 0.921). The treatment of rats with fluoxetine (5 mg/kg/day, orally) for 21 days caused a significant reduction in the number of hypothalamic 5-ht7 receptor binding sites. These data suggest that the 5-ht7 receptor binding site is expressed in rat hypothalamus and that this receptor binding site is down-regulated after a chronic increase in the synaptic level of 5-HT.
Assuntos
Fluoxetina/farmacologia , Hipotálamo/ultraestrutura , Pindolol/farmacologia , Receptores de Serotonina/efeitos dos fármacos , Receptores de Serotonina/metabolismo , Animais , Sítios de Ligação , Regulação para Baixo/efeitos dos fármacos , Fluoxetina/metabolismo , Hipotálamo/metabolismo , Cinética , Masculino , Membranas/metabolismo , Pindolol/metabolismo , Ratos , Sensibilidade e Especificidade , Serotonina/metabolismo , TrítioRESUMO
Inhibitors of neuronal norepinephrine (NE) uptake are useful for the treatment of a variety of diseases including depression and urinary incontinence. In the present study, we synthesized and evaluated a novel analog of the potent and selective NE uptake inhibitor, nisoxetine. Thionisoxetine more potently inhibited the uptake of [3H]-NE into hypothalamic synaptosomes and [3H]-nisoxetine binding to the NE transporter than (R)-nisoxetine. The (R) enantiomer of this compound was significantly more potent than the (S) enantiomer, having a Ki of 0.20 nM in [3H]-nisoxetine binding. The (R) enantiomer was approximately 70-fold more potent in inhibiting [3H]-NE uptake when compared to [3H]-5HT uptake. In rats, (R)-thionisoxetine prevented hypothalamic NE depletion by 6-hydroxydopamine with an ED50 of 0.21 mg/kg. Depletion of NE in peripheral nerves was accomplished by the administration of metaraminol to rats. In this paradigm, (R)-thionisoxetine prevented the depletion of heart NE with an ED50 of 3.4 mg/kg and urethral NE with an ED50 of 1.2 mg/kg. Thus, (R)-thionisoxetine is a potent and selective inhibitor of NE uptake in both central and peripheral tissues.